Tardive Dyskinesia: Etiology, Prevention, and Management

References (36)

1. Jackson R, Brams MN, Citrome L, et al. Assessment of the impact of tardive dyskinesia in clinical practice: consensus panel recommendations. Neuropsychiatr Dis Treat. 2021;17:1589–1597. PubMed CrossRef
2. Frei K. Tardive dyskinesia: who gets it and why. Parkinsonism Relat Disord. 2019;59:151–154. PubMed CrossRef
3. OʼBrien A. Comparing the risk of tardive dyskinesia in older adults with first generation and second-generation antipsychotics: a systematic review and meta analysis. Int J Geriatr Psychiatry. 2016;31(7):683–693. PubMed
4. Carbon M, Hsieh CH, Kane JM, et al. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78(3):e264–e278. PubMed CrossRef
5. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21(2):151–156. PubMed CrossRef
6. Jain R, Ayyagari R, Goldschmidt D, et al. Impact of tardive dyskinesia on physical, psychological, social, and professional domains of patient lives: a survey of patients in the United States. J Clin Psychiatry. 2023;84(3):22m14694. PubMed CrossRef
7. McEvoy J, Gandhi SK, Rizio AA, et al. Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia. Qual Life Res. 2019;28(12):3303–3312. PubMed CrossRef
8. Vasan S, Padhy RK. Tardive dyskinesia. StatPearls [Internet]. StatPearls Publishing; 2023. Accessed August 12, 2023. https://www-ncbi-nlm-nih-gov.treadwell.idm.oclc.org/books/NBK448207/
9. Koller WC. Edentulous orodyskinesia. Ann Neurol. 1983;13(1):97–99. PubMed
10. Martino D, Stamelou M, Bhatia KP. The differential diagnosis of Huntingtonʼs disease-like syndromes: ʽred flagsʼ for the clinician. J Neurol Neurosurg Psychiatry. 2013;84(6):650–656. PubMed
11. Titi-Lartey OA, Patel BC. Benign essential blepharospasm. StatPearls [Internet]. StatPearls Publishng; 2023.
12. Jahngir MU, Ameer MA, Patel BC. Meige syndrome. StatPearls [Internet]. StatPearls Publishing; 2023. Accessed August 12, 2023. https://www-ncbi-nlm-nihgov.treadwell.idm.oclc.org/books/NBK513358/
13. Freudenreich O. Psychotic Disorders. Springer International Publishing; 2020:190–200.
14. Solmi M, Pigato G, Kane JM, et al. Clinical risk factors for the development of tardive dyskinesia. J Neurol Sci. 2018;389:21–27. PubMed CrossRef
15. Tsermpini EE, Redenšek S, Dolžan V. Genetic factors associated with tardive dyskinesia: from pre-clinical models to clinical studies. Front Pharmacol. 2021;12:834129. PubMed CrossRef
16. Jankelowitz SK. Treatment of neurolept-induced tardive dyskinesia. Neuropsychiatr Dis Treat. 2013;9:1371–1380. PubMed CrossRef
17. Liou YJ, Lai IC, Liao DL, et al. The human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophrenia. Schizophr Res. 2006;86(1–3):323–325. PubMed CrossRef
18. Rizos EN, Siafakas N, Katsantoni E, et al. Association of the dopamine D3 receptor Ser9Gly and of the serotonin 2C receptor gene polymorphisms with tardive dyskinesia in Greeks with chronic schizophrenic disorder. Psychiatr Genet. 2009;19(2):106–107. PubMed
19. Woerner MG, Saltz BL, Kane JM, et al. Diabetes and development of tardive dyskinesia. Am J Psychiatry. 1993;150(6):966–968. PubMed CrossRef
20. Estevez-Fraga C, Zeun P, López-Sendón Moreno JL. Current methods for the treatment and prevention of drug-induced parkinsonism and tardive dyskinesia in the elderly. Drugs Aging. 2018;35(11):959–971. PubMed CrossRef
21. Citrome L, Isaacson SH, Larson D, et al. Tardive dyskinesia in older persons taking antipsychotics. Neuropsychiatr Dis Treat. 2021;17:3127–3134. PubMed CrossRef
22. Gharabawi GM, Bossie CA, Lasser RA, et al. Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia. Schizophr Res. 2005;77(2–3):119–128. PubMed CrossRef
23. Correll CU, Kane JM, Citrome LL. Epidemiology, prevention, and assessment of tardive dyskinesia and advances in treatment. J Clin Psychiatry. 2017;78(8):1136–1147. PubMed CrossRef
24. American Psychiatric Association. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. 3rd ed. American Psychiatric Publishing; 2020.
25. Bashir HH, Jankovic J. Treatment of tardive dyskinesia. Neurol Clin. 2020;38(2):379–396. PubMed CrossRef
26. Zutshi D, Cloud LJ, Factor SA. Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: experience from a university based movement disorder clinic. Tremor Other Hyperkinet Mov (N Y). 2014;4:266. PubMed CrossRef
27. Yaffe D, Forrest LR, Schuldiner S. The ins and outs of vesicular monoamine transporters. J Gen Physiol. 2018;150(5):671–682. PubMed CrossRef
28. Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017;88(21):2003–2010. PubMed
29. Citrome L. Deutetrabenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2017;71(11). PubMed CrossRef
30. Peckham AM, Nicewonder JA. VMAT2 inhibitors for tardive dyskinesia-practice implications. J Pharm Pract. 2019;32(4):450–457. PubMed CrossRef
31. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997;48(2):358–362. PubMed CrossRef
32. Bhidayasiri R, Jitkritsadakul O, Friedman JH, et al. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018;389:67–75. PubMed CrossRef
33. Csernansky JG, Tacke U, Rusen D, et al. The effect of benzodiazepines on tardive dyskinesia symptoms. J Clin Psychopharmacol. 1988;8(2):154–155. PubMed CrossRef
34. Pappa S, Tsouli S, Apostolou G, et al. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2010;33(6):271–275. PubMed CrossRef
35. Vijayakumar D, Jankovic J. Drug-induced dyskinesia, part 1: treatment of levodopa-induced dyskinesia. Drugs. 2016;76(7):759–777. PubMed CrossRef
36. Macerollo A, Deuschl G. Deep brain stimulation for tardive syndromes: systematic review and meta-analysis. J Neurol Sci. 2018;389:55–60. PubMed CrossRef